Stay updated on Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.

Latest updates to the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.4.2 added to the history and the preceding notices about government funding lapse and operating status (v3.4.1) were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check21 days agoChange DetectedA site-wide funding notice was added, and the page revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.3%

- Check28 days agoChange DetectedAdditions include Show glossary / Hide glossary controls and color-coded highlights for additions and deletions, plus the new revision note v3.4.0. Deletions remove the No FEAR Act data label and the prior revision note v3.3.4.SummaryDifference0.5%

- Check42 days agoChange DetectedOn 2026-01-07, Contacts/Locations and Study Status were added (revision v3.3.4). On 2025-12-15, revision v3.3.3 was deleted.SummaryDifference0.2%

- Check63 days agoChange DetectedAdded a footer note 'Revision: v3.3.3' and removed 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' from the footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check71 days agoChange DetectedAdded Contacts/Locations and Study Status sections to the study record history, updating the list of locations and the current status. A deletion occurred on 2025-09-05.SummaryDifference0.2%

Stay in the know with updates to Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.